158 related articles for article (PubMed ID: 10560958)
21. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
[TBL] [Abstract][Full Text] [Related]
22. Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma.
Yan W; Roach PJ; Bautovich GJ; Learoyd DL; Robinson BG
Clin Nucl Med; 2007 May; 32(5):375-7. PubMed ID: 17452866
[No Abstract] [Full Text] [Related]
23. [Differentiated thyroid cancer in childhood].
Leboulleux S; Hartl D; Baudin E; Schlumberger M
Bull Cancer; 2012 Nov; 99(11):1093-9. PubMed ID: 23149302
[TBL] [Abstract][Full Text] [Related]
24. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
[TBL] [Abstract][Full Text] [Related]
25. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Liu YY; Stokkel MP; Pereira AM; Corssmit EP; Morreau HA; Romijn JA; Smit JW
Eur J Endocrinol; 2006 Apr; 154(4):525-31. PubMed ID: 16556714
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer.
Pellegriti G; Scollo C; Giuffrida D; Vigneri R; Squatrito S; Pezzino V
Thyroid; 2001 Nov; 11(11):1025-30. PubMed ID: 11762711
[TBL] [Abstract][Full Text] [Related]
27. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
28. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Tuttle RM; Fleisher M; Francis GL; Robbins RJ
J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
[TBL] [Abstract][Full Text] [Related]
29. A rare case of a 1.5 mm papillary microcarcinoma of the thyroid presenting with pituitary metastasis.
Simmons JD; Pinson TW; Donnellan KA; Harbarger CF; Pitman KT; Griswold R
Am Surg; 2010 Mar; 76(3):336-8. PubMed ID: 20349670
[No Abstract] [Full Text] [Related]
30. Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained?
McLaughlin CM; Hunter SJ; Bell PM; McCance DR; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 2008 Jul; 69(1):169-70. PubMed ID: 18042175
[No Abstract] [Full Text] [Related]
31. Adrenal metastasis secondary to papillary thyroid carcinoma.
Koutkia P; Safer JD
Thyroid; 2001 Nov; 11(11):1077-9. PubMed ID: 11762719
[TBL] [Abstract][Full Text] [Related]
32. [Papillary cancer of the thyroid: biological behaviour and therapeutic planning (author's transl)].
Spreafico G; Colombo L; Puricelli G
Radiol Med; 1978 Sep; 64(9):1005-20. PubMed ID: 749025
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
Durante C; Haddy N; Baudin E; Leboulleux S; Hartl D; Travagli JP; Caillou B; Ricard M; Lumbroso JD; De Vathaire F; Schlumberger M
J Clin Endocrinol Metab; 2006 Aug; 91(8):2892-9. PubMed ID: 16684830
[TBL] [Abstract][Full Text] [Related]
34. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
35. Papillary thyroid carcinoma: the impact of therapy in 576 patients.
Mazzaferri EL; Young RL; Oertel JE; Kemmerer WT; Page CP
Medicine (Baltimore); 1977 May; 56(3):171-96. PubMed ID: 859443
[No Abstract] [Full Text] [Related]
36. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone.
Hung GU; Ho M; Kao CH
Clin Nucl Med; 2009 May; 34(5):316-7. PubMed ID: 19387216
[No Abstract] [Full Text] [Related]
37. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
38. Role of 131I in the treatment of well differentiated thyroid cancer.
Woodrum DT; Gauger PG
J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
[TBL] [Abstract][Full Text] [Related]
39. [Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours].
Vicek P
Vnitr Lek; 2007; 53(7-8):807-11. PubMed ID: 17915423
[TBL] [Abstract][Full Text] [Related]
40. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
